Home > Publications Database > A Comparison of Operational Definitions for Mild Cognitive Impairment. > print

001     164987
005     20231004170145.0
024 7 _ |a pmc:PMC9484125
|2 pmc
024 7 _ |a 10.3233/JAD-215548
|2 doi
024 7 _ |a pmid:35811516
|2 pmid
024 7 _ |a 1387-2877
|2 ISSN
024 7 _ |a 1875-8908
|2 ISSN
024 7 _ |a altmetric:132586432
|2 altmetric
037 _ _ |a DZNE-2022-01391
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Polcher, Alexandra
|0 P:(DE-2719)2810925
|b 0
|u dzne
245 _ _ |a A Comparison of Operational Definitions for Mild Cognitive Impairment.
260 _ _ |a Amsterdam
|c 2022
|b IOS Press
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1661498025_608
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
500 _ _ |a CC BY-NC: https://creativecommons.org/licenses/by-nc/4.0/
520 _ _ |a Consideration of many tests from different cognitive domains in defining mild cognitive impairment (MCI) is clinical routine, but guidelines for a neuropsychological operationalization of MCI are lacking.Among different operational MCI criteria, to identify those which are best in predicting either conversion to dementia, or a biomarker profile indicative for Alzheimer's disease (AD).Memory-clinic patients without dementia (N = 558; mean age = 66; up to 3 years of follow-up; n = 360 with baseline CSF biomarkers) were included in an observational study using most liberal criteria of cognitive impairment. Four operational definitions of MCI were retrospectively applied: 1) amnestic MCI (word list delayed recall), 2) CERAD total score, 3) comprehensive criteria and 4) base rate corrected CERAD. We compared their accuracy in predicting incident all-cause dementia or AD dementia within three years, or a concurrent CSF Aβ42/tau-ratio indicative of AD.The four definitions overlapped considerably, classified 35-58% of the original sample as impaired and were associated with markedly increased PPVs regarding incident all-cause dementia (39-46% versus 26% of the original sample), AD dementia and AD biomarker positivity. The base-rate corrected MCI definition had the highest prognostic accuracy.he operational criteria examined seem suitable to specify MCI in memory clinic settings, as they identify subjects at high risk of clinical progression. Depending on the neuropsychological battery in use, one or several of these criteria could help to calibrate the clinical judgment of test results, reduce false-positive decisions, and define risk-enriched groups for clinical trials.
536 _ _ |a 353 - Clinical and Health Care Research (POF4-353)
|0 G:(DE-HGF)POF4-353
|c POF4-353
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
650 _ 7 |a Alzheimer’s disease
|2 Other
650 _ 7 |a DSM-5 mild NCD
|2 Other
650 _ 7 |a biomarker
|2 Other
650 _ 7 |a cognition
|2 Other
650 _ 7 |a conversion
|2 Other
650 _ 7 |a dementia
|2 Other
650 _ 7 |a diagnosis
|2 Other
650 _ 7 |a mild cognitive impairment
|2 Other
650 _ 7 |a prognosis
|2 Other
650 _ 2 |a Aged
|2 MeSH
650 _ 2 |a Alzheimer Disease: psychology
|2 MeSH
650 _ 2 |a Amyloid beta-Peptides
|2 MeSH
650 _ 2 |a Biomarkers
|2 MeSH
650 _ 2 |a Cognitive Dysfunction: etiology
|2 MeSH
650 _ 2 |a Disease Progression
|2 MeSH
650 _ 2 |a Humans
|2 MeSH
650 _ 2 |a Male
|2 MeSH
650 _ 2 |a Neuropsychological Tests
|2 MeSH
650 _ 2 |a Retrospective Studies
|2 MeSH
700 1 _ |a Wolfsgruber, Steffen
|0 P:(DE-2719)2810544
|b 1
|u dzne
700 1 _ |a Peters, Oliver
|0 P:(DE-2719)2811024
|b 2
|u dzne
700 1 _ |a Frölich, Lutz
|0 P:(DE-2719)9001189
|b 3
|u dzne
700 1 _ |a Wiltfang, Jens
|0 P:(DE-2719)2811317
|b 4
|u dzne
700 1 _ |a Kornhuber, Johannes
|b 5
700 1 _ |a Hüll, Michael
|b 6
700 1 _ |a Rüther, Eckart
|0 P:(DE-2719)9000273
|b 7
|u dzne
700 1 _ |a Lewczuk, Piotr
|b 8
700 1 _ |a Maier, Wolfgang
|0 P:(DE-2719)2000015
|b 9
|u dzne
700 1 _ |a Jessen, Frank
|0 P:(DE-2719)2000032
|b 10
|u dzne
700 1 _ |a Wagner, Michael
|0 P:(DE-2719)2000057
|b 11
|e Last author
|u dzne
773 _ _ |a 10.3233/JAD-215548
|g p. 1 - 16
|0 PERI:(DE-600)2070772-1
|n 4
|p 1663-1678
|t Journal of Alzheimer's disease
|v 88
|y 2022
|x 1387-2877
856 4 _ |y OpenAccess
|u https://pub.dzne.de/record/164987/files/DZNE-2022-01391.pdf
856 4 _ |y OpenAccess
|x pdfa
|u https://pub.dzne.de/record/164987/files/DZNE-2022-01391.pdf?subformat=pdfa
909 C O |o oai:pub.dzne.de:164987
|p openaire
|p open_access
|p VDB
|p driver
|p dnbdelivery
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 0
|6 P:(DE-2719)2810925
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 1
|6 P:(DE-2719)2810544
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 2
|6 P:(DE-2719)2811024
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 3
|6 P:(DE-2719)9001189
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 4
|6 P:(DE-2719)2811317
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 7
|6 P:(DE-2719)9000273
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 9
|6 P:(DE-2719)2000015
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 10
|6 P:(DE-2719)2000032
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 11
|6 P:(DE-2719)2000057
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-353
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Clinical and Health Care Research
|x 0
914 1 _ |y 2022
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2021-02-04
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2021-02-04
915 _ _ |a Creative Commons Attribution-NonCommercial CC BY-NC 4.0
|0 LIC:(DE-HGF)CCBYNC4
|2 HGFVOC
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2021-02-04
915 _ _ |a OpenAccess
|0 StatID:(DE-HGF)0510
|2 StatID
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2022-11-18
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2022-11-18
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2022-11-18
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2022-11-18
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
|d 2022-11-18
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b J ALZHEIMERS DIS : 2021
|d 2022-11-18
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2022-11-18
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2022-11-18
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2022-11-18
915 _ _ |a IF < 5
|0 StatID:(DE-HGF)9900
|2 StatID
|d 2022-11-18
920 1 _ |0 I:(DE-2719)1011201
|k AG Wagner
|l Neuropsychology
|x 0
920 1 _ |0 I:(DE-2719)1810002
|k AG Dirnagl
|l Vascular Pathology
|x 1
920 1 _ |0 I:(DE-2719)1410006
|k AG Wiltfang
|l Alzheimer Biomarker and Clinical Study Group
|x 2
920 1 _ |0 I:(DE-2719)1011001
|k AG Klockgether
|l Clinical Research- coordination
|x 3
920 1 _ |0 I:(DE-2719)1011102
|k AG Jessen
|l Patient studies cologne
|x 4
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a UNRESTRICTED
980 _ _ |a I:(DE-2719)1011201
980 _ _ |a I:(DE-2719)1810002
980 _ _ |a I:(DE-2719)1410006
980 _ _ |a I:(DE-2719)1011001
980 _ _ |a I:(DE-2719)1011102
980 1 _ |a FullTexts

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21